Founded by seasoned entrepreneurs
PreComb Therapeutics AG was founded in 2018 by two experienced serial Entrepreneurs. Their accumulated and complementory expertises range from cell culture technology, product development, data management, biopharmaceutical development & production and clinical trial supply. From their past leadership roles in InSphero AG and ESBATech, both founders bring in a wealth of experices in technology development, personnel development, company build-up and maturation.
Founders at a glance
- More than 40 years in biotech and pharma
- 3 biotech companies founded
- 15 years of expertise in 3D tissue models
- >50 publications & 9 patents published
- Process development of BEOVU®
- Strong expertise in lab-automation, data science and AI
Jens M. Kelm, PhD
Co-Founder & CEO
Formerly, CSO and CTO at InSphero AG (co-founder) developing physiological 3D models, assays and screening concepts. Holds >50 publications and 9 Patents; Formerly member of the Board of InSphero, co-founder and steering committee member of the competence center for Tissue Engineering and Drug Development (TEDD). Jens holds a PhD in Biology (Cell biology) from the ETH Zürich.
Peter Steiner, PhD
Co-founder, COO and president of the board
Formerly, Executive Director and Head of the Production & Processes department of ESBATech, a Novartis company. Responsible for manufacturing process development of BEOVU® (Brolucizumab, Novartis) and other drug candidates successfully tested in clinical POC trials. Co-founder and member of the board of Insilico Biotechnology AG. Peter holds a PhD in Biology (Biotechnology) from the ETH Zürich.
Olivier Mauti, PhD
Formerly Head of Lab automation at ESBATech and Novartis/NIBR – successfully built state-of-the-art screening facilities and data management systems for high throughput antibody screening. Olivier has strong expertise in data science, AI and laboratory automation. He holds PhD in Neurobiology and was working as PostDoc at Princeton University.
Director / Board of Directors
Patrick is an Anglo-Austrian serial entrepreneur who has been active in early stage businesses since 1990. Throughout his career, he has created and invested in over fifty businesses, exiting twelve via IPO (in London, New York, and Madrid) and twelve via trade sale/licensing deal. Patrick is Chairman of Kinled Holding, a Hong Kong-based private investment company established in 1924, with offices in London, Shanghai, Vienna, and Zurich. Kinled holds a portfolio of more than 50 companies in the life sciences, digital and financial technology industries. He is a Director of Olipan Investments (TdT5) Inc. which specializes in later stage life science private equity investments, and and is a member of the Swiss Corporate Finance and Private Equity Association. A strong advocate of seed funding academic research into innovative business concepts, Patrick is also a Director of the Central European Biotechnology Incubator Accelerator in Vienna.